{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:20Z","timestamp":1788931220543,"version":"build-2803163510"},"reference-count":10,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.1210\/js.2017-00170","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T14:02:07Z","timestamp":1493388127000},"page":"646-649","source":"Crossref","is-referenced-by-count":90,"title":["Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma"],"prefix":"10.1210","volume":"1","author":[{"given":"Anne-C\u00e9cile","family":"Paepegaey","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Lheure","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Ratour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Lethielleux","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Clerc","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Groussin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Descartes University, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"issue":"26","key":"2019041122173010900_B1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2019041122173010900_B2","first-page":"357","article-title":"Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway","volume":"7","author":"Momtaz","year":"2014","journal-title":"Pharm Genomics Pers Med"},{"issue":"5","key":"2019041122173010900_B3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019041122173010900_B4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"issue":"5","key":"2019041122173010900_B5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019041122173010900_B6","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"2019041122173010900_B7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2019041122173010900_B8","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-iduced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2019041122173010900_B9","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2019041122173010900_B10","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/1\/6\/646\/17647166\/js.2017-00170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T12:22:01Z","timestamp":1555071721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/1\/6\/646\/3778173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,4,28]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2017-00170","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,1]]},"published":{"date-parts":[[2017,4,28]]}}}